← Back to home

HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER

Clinical trials for HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER trials appear

Sign up with your email to follow new studies for HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug tested against eight tough cancers

Disease control Ongoing

This early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…

Matched conditions: HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER

Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control

Last updated Mar 31, 2026 12:10 UTC

HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER

Get alerted when new HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER trials appear

New drug tested against eight tough cancers